These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20145632)

  • 1. Allosteric antipsychotics: m4 muscarinic potentiators as novel treatments for schizophrenia.
    Farrell M; Roth BL
    Neuropsychopharmacology; 2010 Mar; 35(4):851-2. PubMed ID: 20145632
    [No Abstract]   [Full Text] [Related]  

  • 2. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.
    Chan WY; McKinzie DL; Bose S; Mitchell SN; Witkin JM; Thompson RC; Christopoulos A; Lazareno S; Birdsall NJ; Bymaster FP; Felder CC
    Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10978-83. PubMed ID: 18678919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive allosteric modulation of M
    Yohn SE; Conn PJ
    Neuropharmacology; 2018 Jul; 136(Pt C):438-448. PubMed ID: 28893562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
    Leach K; Loiacono RE; Felder CC; McKinzie DL; Mogg A; Shaw DB; Sexton PM; Christopoulos A
    Neuropsychopharmacology; 2010 Mar; 35(4):855-69. PubMed ID: 19940843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the mGlu
    Yohn SE; Foster DJ; Covey DP; Moehle MS; Galbraith J; Garcia-Barrantes PM; Cho HP; Bubser M; Blobaum AL; Joffe ME; Cheer JF; Jones CK; Lindsley CW; Conn PJ
    Mol Psychiatry; 2020 Nov; 25(11):2786-2799. PubMed ID: 30116027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M
    Fu L; Luo Y; Niu L; Lin Y; Chen X; Zhang J; Tang W; Chen Y; Jiao Y
    Bioorg Med Chem; 2024 May; 105():117728. PubMed ID: 38640587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.
    Foster DJ; Conn PJ
    Neuron; 2017 May; 94(3):431-446. PubMed ID: 28472649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutual activation of glutamatergic mGlu
    Cieślik P; Woźniak M; Rook JM; Tantawy MN; Conn PJ; Acher F; Tokarski K; Kusek M; Pilc A; Wierońska JM
    Psychopharmacology (Berl); 2018 Oct; 235(10):2897-2913. PubMed ID: 30054675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M
    Butler CR; Popiolek M; McAllister LA; LaChapelle EA; Kramer M; Beck EM; Mente S; Brodney MA; Brown M; Gilbert A; Helal C; Ogilvie K; Starr J; Uccello D; Grimwood S; Edgerton J; Garst-Orozco J; Kozak R; Lotarski S; Rossi A; Smith D; O'Connor R; Lazzaro J; Steppan C; Steyn SJ
    J Med Chem; 2024 Jul; 67(13):10831-10847. PubMed ID: 38888621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M
    Gould RW; Grannan MD; Gunter BW; Ball J; Bubser M; Bridges TM; Wess J; Wood MW; Brandon NJ; Duggan ME; Niswender CM; Lindsley CW; Conn PJ; Jones CK
    Neuropharmacology; 2018 Jan; 128():492-502. PubMed ID: 28729220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.
    Teal LB; Gould RW; Felts AS; Jones CK
    Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of MK-801-Induced Disruptions in Social Interactions and Working Memory with Simultaneous Administration of LY487379 and VU152100 in Mice.
    Cieślik P; Radulska A; Pelikant-Małecka I; Płoska A; Kalinowski L; Wierońska JM
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31174329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antinociceptive effects of potent, selective and brain penetrant muscarinic M
    Grauer SM; Sanoja R; Poulin D; Rashid H; Jochnowitz N; Calhoun M; Zwilling D; Varty GB; Rosahl TW; Meziane H; Mittlelhaeuser C; Mazzola R; Morrow J; Smith SM; Henze D; Marcus J
    Brain Res; 2020 Jun; 1737():146814. PubMed ID: 32234514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release.
    Foster DJ; Wilson JM; Remke DH; Mahmood MS; Uddin MJ; Wess J; Patel S; Marnett LJ; Niswender CM; Jones CK; Xiang Z; Lindsley CW; Rook JM; Conn PJ
    Neuron; 2016 Sep; 91(6):1244-1252. PubMed ID: 27618677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors.
    Croy CH; Schober DA; Xiao H; Quets A; Christopoulos A; Felder CC
    Mol Pharmacol; 2014 Jul; 86(1):106-15. PubMed ID: 24807965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery, Optimization, and Biological Characterization of 2,3,6-Trisubstituted Pyridine-Containing M
    Schubert JW; Harrison ST; Mulhearn J; Gomez R; Tynebor R; Jones K; Bunda J; Hanney B; Wai JM; Cox C; McCauley JA; Sanders JM; Magliaro B; O'Brien J; Pajkovic N; Huszar Agrapides SL; Taylor A; Gotter A; Smith SM; Uslaner J; Browne S; Risso S; Egbertson M
    ChemMedChem; 2019 May; 14(9):943-951. PubMed ID: 30920765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous activation of muscarinic and GABA
    Cieślik P; Woźniak M; Tokarski K; Kusek M; Pilc A; Płoska A; Radulska A; Pelikant-Małecka I; Żołnowska B; Sławiński J; Kalinowski L; Wierońska JM
    Behav Brain Res; 2019 Feb; 359():671-685. PubMed ID: 30267715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors.
    Thal DM; Sun B; Feng D; Nawaratne V; Leach K; Felder CC; Bures MG; Evans DA; Weis WI; Bachhawat P; Kobilka TS; Sexton PM; Kobilka BK; Christopoulos A
    Nature; 2016 Mar; 531(7594):335-40. PubMed ID: 26958838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscarinic acetylcholine receptors as CNS drug targets.
    Langmead CJ; Watson J; Reavill C
    Pharmacol Ther; 2008 Feb; 117(2):232-43. PubMed ID: 18082893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.
    Conn PJ; Jones CK; Lindsley CW
    Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.